Equities research analysts at Maxim Group initiated coverage on shares of Prenetics Global (NASDAQ:PRE – Get Free Report) in a report released on Monday, Briefing.com reports. The brokerage set a “buy” rating and a $41.00 price target on the stock. Maxim Group‘s target price indicates a potential upside of 136.31% from the company’s previous close. […]

Analysts at Morgan Stanley began coverage on shares of Incyte (NASDAQ:INCY – Get Free Report) in a research report issued on Tuesday. The brokerage set an “equal weight” rating and a $119.00 price target on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would suggest a potential upside of 2.34% from the company’s current price. […]

Chardan Capital began coverage on shares of MannKind (NASDAQ:MNKD – Free Report) in a research note published on Monday, Marketbeat reports. The firm issued a buy rating and a $10.00 target price on the biopharmaceutical company’s stock. Several other research analysts have also commented on MNKD. Zacks Research raised shares of MannKind from a “strong […]

Investment analysts at Stephens initiated coverage on shares of ACI Worldwide (NASDAQ:ACIW – Get Free Report) in a report released on Friday. The brokerage set an “equal weight” rating and a $56.00 price target on the technology company’s stock. Stephens’ target price suggests a potential upside of 6.29% from the company’s current price. Other equities […]

Equities researchers at William Blair started coverage on shares of Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) in a report issued on Wednesday. The brokerage set an “outperform” rating on the stock. A number of other brokerages have also issued reports on JSPR. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics […]

Leerink Partners assumed coverage on shares of Connect Biopharma (NASDAQ:CNTB – Free Report) in a research report released on Monday, Marketbeat.com reports. The brokerage issued an outperform rating and a $4.00 price objective on the stock. Other research analysts have also issued research reports about the company. Wall Street Zen raised Connect Biopharma from a […]

Leerink Partners started coverage on shares of Q32 Bio (NASDAQ:QTTB – Free Report) in a report issued on Monday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $40.00 target price on the stock. Several other equities research analysts have also recently weighed in on QTTB. Morgan Stanley started coverage on Q32 Bio […]